Long Term Treatment of Multiple Sclerosis with Interferon-?? May Be Cost Effective
- 1 July 2000
- journal article
- review article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 18 (1), 45-53
- https://doi.org/10.2165/00019053-200018010-00005
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MSNeurology, 1999
- Randomised, double blind, placebo controlled study of interferon beta -1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curvesJournal of Neurology, Neurosurgery & Psychiatry, 1999
- Neurodegeneration in Multiple Sclerosis: Relationship to Neurological DisabilityThe Neuroscientist, 1999
- A comprehensive assessment of the cost of multiple sclerosis in the United StatesMultiple Sclerosis Journal, 1998
- Economic Evaluation of Multiple Sclerosis in the UK, Germany and FrancePharmacoEconomics, 1998
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Mechanisms of action of interferon-? in multiple sclerosisSpringer Seminars in Immunopathology, 1996
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- Recent views on amyotrophic lateral sclerosis with emphasis on electrophysiological studiesMuscle & Nerve, 1987
- Rating neurologic impairment in multiple sclerosisNeurology, 1983